Literature DB >> 22308143

Which is the IDEAL peginterferon for Hepatitis C: a meta-analysis of both pegylated interferons in the treatment of HCV-infected patients.

Frank Tacke.   

Abstract

Entities:  

Year:  2010        PMID： 22308143      PMCID： PMC3269088     

Source DB:  PubMed          Journal:  Hepat Mon        ISSN： 1735-143X            Impact factor:   0.660


× No keyword cloud information.
  11 in total

Review 1.  Management of nonresponsive hepatitis C.

Authors:  François Bailly; Si Nafa Si Ahmed; Pierre Pradat; Christian Trepo
Journal:  Expert Rev Anti Infect Ther       Date:  2010-04       Impact factor: 5.091

2.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

Authors:  John G McHutchison; Eric J Lawitz; Mitchell L Shiffman; Andrew J Muir; Greg W Galler; Jonathan McCone; Lisa M Nyberg; William M Lee; Reem H Ghalib; Eugene R Schiff; Joseph S Galati; Bruce R Bacon; Mitchell N Davis; Pabak Mukhopadhyay; Kenneth Koury; Stephanie Noviello; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; Mark S Sulkowski
Journal:  N Engl J Med       Date:  2009-07-22       Impact factor: 91.245

3.  Do differences in pegylation of interferon alfa matter?

Authors:  Stefan Zeuzem
Journal:  Gastroenterology       Date:  2009-11-21       Impact factor: 22.682

4.  Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials.

Authors:  Tahany Awad; Kristian Thorlund; Goran Hauser; Davor Stimac; Mahasen Mabrouk; Christian Gluud
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

5.  [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection].

Authors:  C Sarrazin; T Berg; R S Ross; P Schirmacher; H Wedemeyer; U Neumann; H H Schmidt; U Spengler; S Wirth; H H Kessler; M Peck-Radosavljevic; P Ferenci; W Vogel; D Moradpour; M Heim; M Cornberg; U Protzer; M P Manns; W E Fleig; M M Dollinger; S Zeuzem
Journal:  Z Gastroenterol       Date:  2010-01-29       Impact factor: 2.000

6.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

Authors:  Maria Grazia Rumi; Alessio Aghemo; Gian Maria Prati; Roberta D'Ambrosio; Maria Francesca Donato; Roberta Soffredini; Ersilio Del Ninno; Antonio Russo; Massimo Colombo
Journal:  Gastroenterology       Date:  2009-09-18       Impact factor: 22.682

8.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

9.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

10.  The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis.

Authors:  Seyed Moayed Alavian; Bita Behnava; Seyed Vahid Tabatabaei
Journal:  Hepat Mon       Date:  2010-06-01       Impact factor: 0.660
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.